Loading...
Market
What will be the revenue from Merck's CN201 therapy in its first year post-approval?
2
Resolution / Starting Odds
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Merck's financial reports and press releases
Story
Merck Acquires CN201 Therapy for $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. The deal involves an upfront payment of $700 million in cash, with potential earnouts of up to $600 million, bringing the total transaction value to $1.3 billion. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance Merck’s pipeline with potential applications in treating B-cell malignancies and autoimmune diseases. This strategic acquisition highlights Merck's commitment to expanding its capabilities in immune disease therapeutics.
View original story
Similar markets
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
B-cell malignancies • 25%
Autoimmune diseases • 25%
Both • 25%
Neither • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%